Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review
Abstract
Share and Cite
Hoch, J.S.; Brown, M.B.; McMahon, C.; Nanson, J.; Rozmovits, L. Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review. Curr. Oncol. 2014, 21, 263-266. https://doi.org/10.3747/co.21.2128
Hoch JS, Brown MB, McMahon C, Nanson J, Rozmovits L. Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review. Current Oncology. 2014; 21(5):263-266. https://doi.org/10.3747/co.21.2128
Chicago/Turabian StyleHoch, J.S., M.B. Brown, C. McMahon, J. Nanson, and L. Rozmovits. 2014. "Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review" Current Oncology 21, no. 5: 263-266. https://doi.org/10.3747/co.21.2128
APA StyleHoch, J. S., Brown, M. B., McMahon, C., Nanson, J., & Rozmovits, L. (2014). Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review. Current Oncology, 21(5), 263-266. https://doi.org/10.3747/co.21.2128